Cetilistat (ATL-962), a Novel Pancreatic Lipase Inhibitor, Ameliorates Body Weight Gain and Improves Lipid Profiles in Rats

Abstract

Cetilistat is a novel inhibitor of pancreatic lipase. The aim of this report is to evaluate the anti-obesity action of cetilistat in diet-induced obesity (DIO) rats. Cetilistat inhibited rat and human pancreatic lipase activity with an IC₅₀ of 54.8 nmol/l, and 5.95 nmol/l, respectively, meaning that it is 9.2 times more potent for human pancreatic lipase than for that of rat. Cetilistat was orally administered simultaneously with fat emulsion to Sprague-Dawley rats. Plasma triglyceride (TG) concentrations were measured before and after oral fat loading. The elevation in plasma triglyceride concentration by oral fat loading was reduced by cetilistat in a dose-dependent manner at 3, 10, 30, and 100 mg/kg, indicating that cetilistat reduces intestinal fat absorption in rats. Cetilistat was administered to DIO F344 rats as food admixture in a high-fat diet at 4.9, 14.9, or 50.7 mg/kg/day for three weeks. Both triglyceride and nonesterified fatty acid content in the feces were dose-dependently and drastically increased, suggesting the intestinal breakdown of fat and excretion. Body weight (BW) gain and white adipose tissue (WAT) weight were reduced in a dose-dependent manner. In addition, leptin, TG, and total cholesterol (TC) in plasma were reduced and there were no reports of oily stools. These results suggest that cetilistat ameliorates obesity and hyperlipidemia in DIO rats, a plausible animal model of the most common type of human obesity.

Key words

nonesterified fatty acid - high-fat diet - triglyceride - total cholesterol - white adipose tissue - visceral fat

References

• 1 Baile CA, Della-Fera MA, Martin RJ. Regulation of metabolism and body fat mass by leptin.  Annu Rev Nutr. 2000;  20 105-127
• 2 Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome.  Nature. 2006;  444 881-887
• 3 Diabetes Atlas Committee .International Diabetes Federation. In: Diabetes Atlas Executive Summary 2nd edition. 2003
• 4 Kelner K, Helmuth L. Obesity: What is to be done?.  Science. 2003;  299 846-860
• 5 Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, Valensi P. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.  Int J Obes. 2007;  31 494-499
• 6 Gura T. Obesity drug pipeline not so fat.  Science. 2003;  299 849-852
• 7 Zhang H, Proenca R, Maffei M, Barone M, Leopold L, Friedman FM. Positional cloning of the mouse obese gene and its human homolog.  Nature. 1994;  372 425-432
• 8 Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review.  Obes Rev. 2007;  8 21-34
• 9 Harvary P, Sidler W, Meister W, Vetter W, Wolfer H. The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase.  J Biol Chem. 1991;  266 2021-2027
• 10 Hogan S, Fleury A, Hadvery P, Lengsfeld H, Meier MK, Triscari J, Sullivan AC. Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase.  Int J Obes. 1987;  11 ((Suppl. 3)) 35-42
• 11 Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Kopperschaar HPF, Krempf M. For the European Multicentre Orlistat Study Group: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients.  Lancet. 1998;  352 167-172
• 12 Sharrett AR, Chambless LE, Heiss G, Paton CC, Patsch W. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women: The Atherosclerosis Risk in Communities (ARIC) Study.  Arterioscler Thromb Vascu Biol. 1995;  15 2122-2129
• 13 Cancelas J, Prieto PG, Villanueva-Penacarrillo ML, ValVerde I, Malaisse WJ. Effects of an olive-oil enriched diet on glucagon-like peptide 1 release and intestinal content, plasma insulin concentration, glucose tolerance and pancreatic insulin content in an animal model of type 2 diabetes.  Horm Metab Res. 2006;  38 98-105
• 14 Baggio LL, Drucker D. Biology of incretins: GLP-1 and GIP.  Gastroenterology. 2007;  132 2131-2157

Correspondence